Agents directed against a cis RGMa/neogenin interaction or lipid rafts and use of the same in methods of treatment
AssigneeUniversity Health Network
InventorsPhilippe P. Monnier, Nardos G. Tassew
Life of this patent
Estimating the term…
Abstract
Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.
Claims6
A method of treating retinitis pigmentosa, ischemia, multiple sclerosis, spinal cord injury, or optic nerve injury wherein the method comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and
- (i) a peptide consisting of amino acids 1 to 383 of SEQ ID NO:
- 1, or
- (ii) a peptide consisting of amino acids 1 to 417 of SEQ ID NO:
- 11.
A method of treating retinitis pigmentosa, ischemia, multiple sclerosis, spinal cord injury, or optic nerve injury, wherein the wherein the method comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a peptide consisting of an amino acid sequence having at least 95% identity to an amino acid sequence consisting of amino acids 1 to 383 of SEQ ID NO:1 or an amino acid sequence consisting of amino acids 1 to 417 of SEQ ID NO:11, which disrupts a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin.
Dependencies are inferred from the claim text.